Clinical trials: Somatoform Disorders
Body Dysmorphic Disorders
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin.
- Trial name
- NCT04656301
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New York State Psychiatric Institute
Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
The purpose of this study is to learn more about two different types of psychotherapy to help individuals who have body dysmorphic disorder (BDD).
- Conditions
- Body Dysmorphic Disorder, Obsessive-Compulsive Spectrum Disorder, Anxiety Disorders, Somatoform Disorders
- Trial name
- NCT01453439
- Testing
- Cognitive Behavioral Therapy, Supportive Psychotherapy
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Body Dysmorphic Disorder
Fluoxetine in Pediatric Body Dysmorphic Disorder
This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.
- Trial name
- FDA BDD (NCT00245635)
- Testing
- Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Montefiore Medical Center
Somatization Disorder
Assessment of Somatic Symptom in Chinese Community-Dwelling People
With the rapid aging and worsening psychological problems worldwide, the special focus on somatic symptom and other psychological diseases of the older population is needed.
- Trial name
- NCT04815863
- Testing
- Assessment of somatic symptom disorder with SSS-CN, Assessment of depressive symptoms disorder with PHQ-9, Assessment of anxiety disorder with GAD-7
- Where
- 2 sites in China
- Volunteers
- 9,110 people
- Sponsor
- RenJi Hospital
Anxiety
Tenoten® in the Treatment of Somatoform, Stress-related and Other Neurotic Disorders
The purposes of this study are: To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.
- Trial name
- NCT03036293
- Testing
- Tenoten
- Where
- 22 sites in Kazakhstan, Russia
- Volunteers
- 390 people
- Sponsor
- Materia Medica Holding